Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results ...
AbbVie stock falls 3.6% despite Q4 earnings beat of $2.71/share and 2026 guidance topping estimates as oncology and aesthetics revenue decline.
Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into supply ...
We came across a bullish thesis on AbbVie Inc. on Disruptive Analytics ’ Substack by Magnus Ofstad. In this article, we will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results